Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AngioSoma
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
AngioSoma historically described itself as a clinical-stage biotechnology company focused on improving endovascular interventions and standard-of-care treatments for peripheral artery disease through products such as Liprostin, but later pivoted toward wellness and dietary supplements and subsequently changed its name and business focus to GlobeStar Therapeutics in July 2021.[1][3][4][5]
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small moleculeDeviceNon-pharmacological therapyDietary supplement
- Industry
- Biotech
Beyond the preview
Go deeper on AngioSoma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioSoma.